ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE...
Pharmaceutical
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report
ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market...
Panome Bio Multi-omics Laboratory Enhances Clinical Capabilities with CLIA Certification
ST. LOUIS, July 29, 2025 /PRNewswire/ -- Panome Bio, a leader in advanced proteomic, metabolomic and transcriptional profiling technologies, announced...
Briya Unveils Briya AIRE, First Clinical-Grade AI Platform to Accelerate Medical and Epidemiological Research
Custom Built AI Research Environment Enables Faster Discovery and Reduced Costs Across Life Sciences and Medical Research NEW YORK, July...
Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how AI can streamline patient recruitment and reach the unreachable. Attendees will gain insight into...
ArcheHealth™ to Showcase AI-Powered Healthcare Supply Chain Solution at AHRMM25
Novel solution delivers numerous financial and operational benefits, including insights that improve cash flow, reduce supply and labor costs, and...
ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025
Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions BOSTON, July 29, 2025 /PRNewswire/...
Unlearn Appoints Its First Vice President of Product
Kwame Marfo brings more than 15 years of experience at the intersection of life sciences, health technology, and product innovationSAN...
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Quoin Pharmaceuticals Provides Product Portfolio Update
Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the...
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs...
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted...
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
PDUFA Fee Waiver comes Days before Planned Submission of New Drug ApplicationKANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) --...
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients...
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to...
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net...
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than...
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced...